Cost Effectiveness of Human Papillomavirus-16/18 Genotyping in Cervical Cancer Screening

[21] Lorincz AT(2010)Cervical cancer screening in Australia: modelled evaluation of the impact of changing the recommended interval from two to three years BMC Public Health 10 734-165

[22] Wacholder S(2010)Methods of model calibration: observations from a mathematical model of cervical cancer Pharmacoeconomics 28 995-S27

[23] Sherman M(1997)International incidence rates of invasive cervical cancer before cytological screening Int J Cancer 71 159-2323

[24] Scott DR(2012)Screening and cervical cancer cure: population based cohort study Bmj 344 e900-401

[25] Castle PE(2013)2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors J Low Genit Tract Dis 17 S1-243

[26] Stoler MH(2010)Short-term outcome of cervical intraepithelial neoplasia grade 2: considerations for management strategies and reproducibility of diagnosis Anticancer Res 30 2319-842

[27] Wright TC(2004)Discounting health outcomes in economic evaluation: the ongoing debate Value Health 7 397-1924

[28] Sharma A(2001)The practice of discounting in economic evaluations of healthcare interventions Int J Technol Assess Health Care 17 236-2038

[29] Wright TL(2012)Model parameter estimation and uncertainty: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-6 Value Health 15 835-641

[30] Behrens CM(2012)Primary cervical cancer screening with HPV testing compared with liquid-based cytology: results of round 1 of a randomised controlled trial—the HPV FOCAL Study Br J Cancer 107 1917-88

[21] Lorincz AT(2010)Cervical cancer screening in Australia: modelled evaluation of the impact of changing the recommended interval from two to three years BMC Public Health 10 734-165

[22] Wacholder S(2010)Methods of model calibration: observations from a mathematical model of cervical cancer Pharmacoeconomics 28 995-S27

[23] Sherman M(1997)International incidence rates of invasive cervical cancer before cytological screening Int J Cancer 71 159-2323

[24] Scott DR(2012)Screening and cervical cancer cure: population based cohort study Bmj 344 e900-401

[25] Castle PE(2013)2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors J Low Genit Tract Dis 17 S1-243

[26] Stoler MH(2010)Short-term outcome of cervical intraepithelial neoplasia grade 2: considerations for management strategies and reproducibility of diagnosis Anticancer Res 30 2319-842

[27] Wright TC(2004)Discounting health outcomes in economic evaluation: the ongoing debate Value Health 7 397-1924

[28] Sharma A(2001)The practice of discounting in economic evaluations of healthcare interventions Int J Technol Assess Health Care 17 236-2038

[29] Wright TL(2012)Model parameter estimation and uncertainty: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-6 Value Health 15 835-641

[30] Behrens CM(2012)Primary cervical cancer screening with HPV testing compared with liquid-based cytology: results of round 1 of a randomised controlled trial—the HPV FOCAL Study Br J Cancer 107 1917-88